How MedTech companies assess exposure to standard essential patents as connectivity standards become embedded in devices, including licensing strategy and litigation risk.
Olivier Marchand
Regenerative Agriculture Manager
Nestlé
Olivier Marchand is Regenerative Agriculture Manager at Nestlé, with over 20 years of experience driving sustainability, quality, and responsible practices across value chains.
With a strong background in purchasing, quality assurance, and agriculture, he has worked across Europe, Africa, Latin America, and Asia, bringing a global and cross-cultural perspective. He focuses on strengthening traceability, sustainability, and trust, helping meet growing consumer expectations around product origin, production methods, and social responsibility.
Sébastien Roumegous
CEO
BIOSPHERES
Sébastien Roumegous is a soil specialist and impact entrepreneur focused on scaling regenerative agriculture. As CEO of BIOSPHERES, Europe’s leading regenerative agriculture company, he supports businesses and public actors in transitioning toward high-performing, ecosystem-restoring farming systems.
With over 15 years of experience across 22 countries and 200,000 hectares in transition, his work combines technical expertise with a pragmatic, field-driven approach to improve soil health, biodiversity, and farmers’ livelihoods. Raised in a farming environment in southern France, he brings a grounded, results-oriented perspective to large-scale agricultural transformation. He recently published his first book on regenerative agriculture.
How MedTech companies decide when to patent device innovation and when to rely on trade secret protection, balancing enforcement leverage, disclosure risk, and reverse engineering realities.
Eda Stark
Global IP Transactions & Litigation Managing Counsel
Olympus
Gabriel Olander
Associate GC, IP Strategy
Intuitive
How and why US-based companies are using Brazilian litigation as part of their cross-border enforcement and settlement strategies, including the ease of injunctions, speed and increasing success in tech-based cases.
How companies design settlements that address multiple products and patents while managing future releases, portfolio scope, and downstream risk.
Practical challenges in assessing infringement, preserving evidence, and aligning litigation strategy when products evolve through frequent updates and feature releases.
Claim construction strategy for complex product ecosystems, where alleged infringement spans hardware, software, cloud services, and third-party components.
Peter Flora
Chief of IP
AngioDynamics
How defendants identify funded cases in practice and adjust timing, motion strategy, and settlement posture to exploit funder economics and decision constraints.
How and when to use ex parte re-examination to narrow or reshape asserted claims, weaken infringement theories, and create leverage without the visibility or estoppel risks of IPR.